Physician profile
David E Kartzinel
NPI 1700842226
$3,284.73
in general payments reported to CMS, 2019-2025
31 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,012 · 2020: $263 · 2021: $489 · 2022: $347 · 2023: $578 · 2024: $323 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $922 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $921.79 |
| Education | $251.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien Lp | $750.06 | 2019 | |
| Abbvie INC. | $676.84 | 2020-2025 | |
| Astellas Pharma US INC | $427.50 | 2023-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $248.99 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $128.65 | 2023-2025 | |
| Therapeuticsmd, INC. | $124.44 | 2019-2022 | |
| Coloplast Corp | $122.99 | 2025 | |
| Allergan, INC. | $116.58 | 2019-2020 | |
| Pfizer INC. | $80.19 | 2020-2023 | |
| Exeltis, USA INC. | $56.00 | 2020-2024 | Slynd |
| Hologic Sales and Service, LLC | $48.95 | 2021-2024 | Aptima, Thinprep 2000 Processor |
| Myovant Sciences INC. | $42.57 | 2021-2022 | |
| Kci USA, INC. | $38.80 | 2020 | |
| Roche Diagnostics Corporation | $37.15 | 2019 | |
| Molnlycke Health Care US, LLC | $35.26 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $31.20 | 2021 | |
| Daiichi Sankyo INC. | $28.40 | 2019 | |
| Becton, Dickinson and Company | $28.33 | 2022 | |
| Sumitomo Pharma America, INC. | $24.69 | 2024 | Myfembree |
| Smith+Nephew, INC. | $24.56 | 2024 | Renasys Touch |
| Kerecis Limited | $24.34 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Organon LLC | $24.11 | 2025 | Jada System |
| Sage Therapeutics, LLC | $22.76 | 2024 | |
| Evofem Biosciences, INC. | $22.71 | 2022 | |
| Octapharma USA, INC. | $22.24 | 2025 | Fibryga |
| Davol INC. | $20.27 | 2023 | Arista Ah Flexitip |
| Shield Therapeutics INC | $18.18 | 2023 | Accrufer |
| Mylan Pharmaceuticals INC. | $17.14 | 2021 | |
| Avion Pharmaceuticals | $14.40 | 2022 | |
| Lupin INC. | $14.04 | 2019 | |
| Agile Therapeutics, INC. | $12.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kartzinel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.